Journal of Cardiovascular Pharmacology最新文献_第4页

SGLT2 Inhibitors in the Elderly: Redefining Cardiac Care Beyond Age. SGLT2抑制剂在老年人中的应用：重新定义年龄以外的心脏护理。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001680

Marco Giuseppe Del Buono, Simone Filomia, Gianluigi Saponara, Tommaso Sanna

引用次数: 0

Pantothenate Kinase 1 Identified as a Direct Target of SGLT2 Inhibitors in the Heart. 泛酸激酶1 （PANK1）被确定为心脏中SGLT2抑制剂的直接靶点。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001689

Ghadir Amin, George W Booz, Fouad A Zouein

引用次数: 0

Comparing the Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors Among Nonolder and Older Patients: A Systematic Review and Meta-Analysis. 比较钠-葡萄糖共转运蛋白2抑制剂在非老年和老年患者中的疗效：一项系统回顾和荟萃分析

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001659

Izuki Yamashita, Tomohiro Fujisaki, Francisco J Romeo, Daisuke Sueta, Eiichiro Yamamoto, Kenichi Tsujita

{"title":"Comparing the Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors Among Nonolder and Older Patients: A Systematic Review and Meta-Analysis.","authors":"Izuki Yamashita, Tomohiro Fujisaki, Francisco J Romeo, Daisuke Sueta, Eiichiro Yamamoto, Kenichi Tsujita","doi":"10.1097/FJC.0000000000001659","DOIUrl":"10.1097/FJC.0000000000001659","url":null,"abstract":"Abstract: Large scale randomized trials have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors can reduce cardiovascular events in patients with cardiovascular disease or with increased risks of cardiovascular disease. However, the evidence from older patients is limited. To compare the efficacy of SGLT2 inhibitors among nonolder and older patients, we have searched PubMed, Cochrane Central, and Embase until February 2023 for randomized controlled trials investigating SGLT2 inhibitors in older (age ≥65 years) patients with diabetes mellitus, chronic kidney disease, and chronic heart failure. The primary outcome was a composite outcome of cardiovascular death, acute myocardial infarction, and stroke. The secondary outcomes were exacerbation of heart failure, kidney disease progression, and a composite of cardiovascular death and heart failure. Our search identified 11 randomized controlled trials with a total of 79,370 patients. SGLT2 inhibitors were associated with a reduced risk of the primary outcome in the total cohort [hazard ratio (HR): 0.91; confidence intervals (CI), 0.84-0.99] with concordant results in both nonolder and older populations (HR: 0.96; CI, 0.88-1.05, HR: 0.87; CI, 0.75-1.01, respectively) without subgroup differences ( P = 0.23), and a reduced risk of developing the composite of cardiovascular death and heart failure exacerbation in both nonolder and older populations (HR: 0.77; CI, 0.67-0.87, HR: 0.76; CI, 0.71-0.82, respectively) without subgroup differences ( P = 0.96). A meta-analysis could not be performed for the other outcomes. These results suggested that SGLT2 inhibitors were similarly associated with reduced risks of cardiovascular events across the spectrum of nonolder and older patients with risk factors for developing cardiovascular disease.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"329-337"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship Between Aldehyde Dehydrogenase 2 Gene Polymorphism and Vasodilative Effect of Nitroglycerin on Coronary Arteries. ALDH2基因多态性与硝酸甘油对冠状动脉血管扩张作用的关系

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001682

Kai Zhang, Chi He, Yaliang Tong, Yuquan He

{"title":"Relationship Between Aldehyde Dehydrogenase 2 Gene Polymorphism and Vasodilative Effect of Nitroglycerin on Coronary Arteries.","authors":"Kai Zhang, Chi He, Yaliang Tong, Yuquan He","doi":"10.1097/FJC.0000000000001682","DOIUrl":"10.1097/FJC.0000000000001682","url":null,"abstract":"Abstract: Aldehyde dehydrogenase 2 (ALDH2) is a key enzyme that facilitates the biologic metabolism of nitroglycerin. However, no study investigated the association between ALDH2 gene polymorphism and the vasodilation of coronary arteries after intracoronary administration of nitroglycerin. In this study, we enrolled 427 patients with suspected angina pectoris. ALDH2 genotyping was performed and all patients were given 200 µg nitroglycerin in the right coronary artery during the coronary angiography. The invasive hemodynamic parameters including systolic blood pressure (SBP), diastolic blood pressure, and heart rate were monitored. The reference diameter and stenosis diameter of the right coronary artery were measured with the Stenosis Analysis 1.6 software. Both wild-type and mutant-type groups exhibited significant decreases in SBP, diastolic blood pressure values, and increases in heart rate value after administration of nitroglycerin ( P < 0.05). The wild-type group showed significantly higher absolute difference values in SBP than the mutant-type group ( P < 0.05). The mutant-type group exhibited significantly lower difference values and rates of change in reference diameter than the wild-type group [0.3 ± 0.3 vs. 0.5 ± 0.2, P < 0.001 for the difference value of diameter; 9.6 ± 9.5 vs. 15.8 ± 8.5, P < 0.001 for the rate of change (%)]. Conversely, no differences were observed between the wild-type and mutant-type groups in terms of the difference value and rate of change of the stenosis diameter ( P > 0.05). In conclusion, ALDH2 gene polymorphism (Glu504Lys) is associated with changes in invasive hemodynamic parameters and coronary artery diameter after intracoronary injection of nitroglycerin.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"358-363"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Procyanidin B2 Attenuates Pathologic Cardiac Fibrosis and Inflammation: Role of PPARγ. 原花青素B2减轻病理性心肌纤维化和炎症：PPARγ的作用。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001684

Chun Xia Li, Ruo Man Wu, Qian Lin Xie, Fei Wang, Xiao Le Xu

{"title":"Procyanidin B2 Attenuates Pathologic Cardiac Fibrosis and Inflammation: Role of PPARγ.","authors":"Chun Xia Li, Ruo Man Wu, Qian Lin Xie, Fei Wang, Xiao Le Xu","doi":"10.1097/FJC.0000000000001684","DOIUrl":"10.1097/FJC.0000000000001684","url":null,"abstract":"Abstract: Procyanidin B2 (PB2) is a prominent procyanidin isomer. Its effects and mechanisms in cardiac remodeling are not fully understood. Peroxisome proliferator-activated receptor gamma (PPAR-γ) plays a crucial role in regulating cardiac hypertrophy, fibrosis, and inflammation. This study aims to investigate the effect of PB2 on pathologic cardiac fibrosis and inflammation, focusing on the underlying mechanisms involving PPAR-γ. In vitro, cardiac fibrosis was induced in cardiac fibroblasts using angiotensin II. In vivo, a mouse model of pathologic cardiac fibrosis was generated through transverse aortic constriction to induce pressure overload. We found that PB2 inhibited proliferation, differentiation, collagen accumulation, and the NF-κB inflammation pathway in cardiac fibroblasts triggered by angiotensin II. These inhibitory effects were negated by the PPAR-γ antagonist GW9662 and RNA interference. In addition, PB2 directly elevated PPAR-γ expression in cardiac fibroblasts. Similarly, PB2 alleviated transverse aortic constriction-induced cardiac dysfunction, myocardial fibrosis, and inflammation in mice. These cardioprotective effects of PB2 in vivo were counteracted by coadministration with GW9662. Correspondingly, the upregulation of PPAR-γ protein expression by PB2 in pressure-overloaded hearts was also counteracted by GW9662 coadministration. In conclusion, this study demonstrates that PB2 exerts protective effects against pathologic cardiac fibrosis and inflammation through a PPAR-γ-dependent mechanism.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"338-349"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coupling Interval Ratio to Predict the Beta-Blocker Response Against Premature Ventricular Complexes. 偶联间隔比预测β受体阻滞剂对早衰心室复合体的反应。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001686

Hasan Atmaca, Ertan Yetkin

{"title":"Coupling Interval Ratio to Predict the Beta-Blocker Response Against Premature Ventricular Complexes.","authors":"Hasan Atmaca, Ertan Yetkin","doi":"10.1097/FJC.0000000000001686","DOIUrl":"10.1097/FJC.0000000000001686","url":null,"abstract":"Abstract: Despite the wide-spread use of beta-blockers, unpredictable response and overall low efficacy are the major pitfalls of beta-blocker use for premature ventricular complexes (PVCs). Accordingly, we aimed to reveal Holter-guided electrocardiographic criteria to predict the beta-blocker responder ones of PVCs. A total of 89 patients who had pre- and post-treatment Holter electrocardiogram recordings and fulfilled the inclusion criteria were retrospectively included in the study. Holter recordings were screened for heart rate variability, number of PVCs, heart rate, pre- and postcoupling intervals (CIs) in 3 different time intervals (24:00-08:00 am , 08:00 am -16:00 pm and 16:00 pm -24:00). Forty-three patients were defined as beta-blocker responder group with respect to 70% decrease in PVCs burden. Heart rate variability analysis revealed that there were not statistically significant differences between beta-blocker responder and nonresponder groups. CI ratio [(post-PVC CI + pre-PVC CI)/pre-PVC CI] of responder and nonresponder groups in 24.00 to 8.00 am time interval was statistically different (3.19 vs. 2.91, P = 0.006, respectively). Logistic regression analysis revealed that CI ratios of the PVCs during the 24:00-08:00 am intervals have significantly associated with the beta-blocker responsiveness for PVCs (odds ratio, 9.54; 95% confidence interval, 1.89-48.7; P value: 0.006). Nighttime increased CI ratio, that is, shorter CI time has been found to be an independent predictor of beta-blocker response against PVCs. Therefore, beta-blockers may be preferably recommended for PVCs, especially in those with shorter CI or increased CI ratio.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"364-368"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gene- and cell-based therapy in cardiovascular diseases. 心血管疾病的基因和细胞治疗。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-30 DOI: 10.1097/FJC.0000000000001707

Cuijuan Zhang, Zhihang Du, Rui Chen, Xiaojing Liu, Dan Li

引用次数: 0

Sodium-glucose transporter-2 inhibitors: safety and efficacy in patients with peripheral artery disease. 钠-葡萄糖转运蛋白-2抑制剂在外周动脉疾病患者中的安全性和有效性

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-29 DOI: 10.1097/FJC.0000000000001703

Katelyn J Galli, Mark Wadid, Youssef Bessada

{"title":"Sodium-glucose transporter-2 inhibitors: safety and efficacy in patients with peripheral artery disease.","authors":"Katelyn J Galli, Mark Wadid, Youssef Bessada","doi":"10.1097/FJC.0000000000001703","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001703","url":null,"abstract":"The objective of this review is to assess the safety and efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) in patients with peripheral arterial disease (PAD). A literature search of PubMed and EMBASE databases (through March 2025) was performed with MeSH words and phrases related to SGLT-2is AND PAD. Articles encompassing original research including results specifying safety and efficacy outcomes particularly in the PAD population were included. Narrative reviews or studies with lack of a substantial PAD population or relevant outcomes were excluded. Our literature search resulted in 289 articles of which 18 were included in the current review. Findings consistently highlighted the cardiovascular benefits SGLT-2is show in PAD patients, supporting their potential role in improving clinical outcomes. Most studies showed neutral or favorable safety regarding lower limb events, suggesting no more risk of adverse limb-related outcomes compared to the non-PAD population. Patients with PAD are likely to see improved outcomes and favorable safety with SGLT-2is, namely, canagliflozin, empagliflozin, and dapagliflozin. Observation of specific PAD populations also suggests that there is no higher risk of adverse limb events, including amputation risk, as compared to patients without PAD. Literature supports the safe and effective use of SGLT-2is in patients with concomitant PAD, regardless of the indication for use. Ongoing studies are needed to assess specific PAD outcomes with SGLT-2is and determine the specific mechanisms proposed for such benefits.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart Rate Lowering with Ivabradine and Burden of Symptoms in Patients with Postural Orthostatic Tachycardia Syndrome. 伊伐布雷定降低心率与体位性心动过速综合征患者的症状负担。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-28 DOI: 10.1097/FJC.0000000000001705

Michele Marchetta, Rocio I Lopez, Austin C Hogwood, Georgia Thomas, Gerardina Abbate, Roshanak Markley, Justin M Canada, Antonio Abbate

{"title":"Heart Rate Lowering with Ivabradine and Burden of Symptoms in Patients with Postural Orthostatic Tachycardia Syndrome.","authors":"Michele Marchetta, Rocio I Lopez, Austin C Hogwood, Georgia Thomas, Gerardina Abbate, Roshanak Markley, Justin M Canada, Antonio Abbate","doi":"10.1097/FJC.0000000000001705","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001705","url":null,"abstract":"Postural Orthostatic Tachycardia Syndrome (POTS) is a clinical syndrome of tachycardia upon standing leading to palpitations, dizziness, chest pain and/or fatigue. An exaggerated norepinephrine response with standing is often present in POTS, but it remains unclear whether the tachycardia is compensatory for a reduced stroke volume or whether the tachycardia is itself causing the symptoms of POTS. We herein report the effects of heart rate lowering with ivabradine, a selective If channel blocker, on symptom burden in patients with POTS. Following ivabradine treatment, there was a significant reduction in the change in heart rate with standing (ΔHR) in all patients from 40 (30-70) to 15 (8-19) bpm (p=0.011), without significant changes in blood pressure. The Malmö score was significantly reduced in all patients from 86 (74-92) to 39 (32-66) (p=0.005). A correlation between ΔHR and the change in Malmö score (R=+0.828; R2 quadratic= 0.635; p<0.001) was present. The parallel improvement in heart rate response and symptoms with ivabradine suggests that the tachycardia response in POTS may not be considered compensatory but rather central to the pathophysiology of POTS symptoms.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COLCHICINE IN ACUTE CORONARY SYNDROMES: A META-ANALYSIS OF 12.602 PATIENTS. 秋水仙碱治疗急性冠状动脉综合征：12.602例患者的荟萃分析

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-28 DOI: 10.1097/FJC.0000000000001706

Luigi Cappannoli, Francesco Fracassi, Cristina Aurigemma, Enrico Romagnoli, Francesco Bianchini, Mattia Lunardi, Rocco Antonio Montone, Lazzaro Paraggio, Carlo Trani, Giovanna Liuzzo, Francesco Burzotta

{"title":"COLCHICINE IN ACUTE CORONARY SYNDROMES: A META-ANALYSIS OF 12.602 PATIENTS.","authors":"Luigi Cappannoli, Francesco Fracassi, Cristina Aurigemma, Enrico Romagnoli, Francesco Bianchini, Mattia Lunardi, Rocco Antonio Montone, Lazzaro Paraggio, Carlo Trani, Giovanna Liuzzo, Francesco Burzotta","doi":"10.1097/FJC.0000000000001706","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001706","url":null,"abstract":"Inflammation is a leading cause of ischaemic heart disease. Aim of the present study is to assess whether treatment with colchicine in patients with ACS is associated with improved cardiovascular outcomes. We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) of patients with acute or recent ACS and treated with colchicine versus placebo. PubMed, Scopus, and the Cochrane Central Register of Controlled Trials databases were searched. The primary endpoint was composite of cardiovascular death, recurrent myocardial infarction (MI), stroke or urgent/unplanned revascularization. Other endpoints were individual components of the primary endpoint, all-cause death, non-cardiovascular death, and diarrhea. PROSPERO ID CRD42025648254. Three RCTs were included, involving 12,602 patients. There was no significant difference in the primary composite endpoint between the colchicine and placebo groups (OR 0.82, 95% CI 0.63-1.07, P=0.15). Analysis of individual components of the primary endpoint also revealed no significant differences between the colchicine vs. placebo groups: cardiovascular deaths (P=0.89), recurrent MI (P=0.17), strokes (P=0.27), urgent/unplanned revascularizations (P=0.14), all-cause death (P=0.95), non-cardiovascular death (P=0.98), and diarrhea (P=0.08). At the leave-one-out analysis, the exclusion of the CLEAR trial resulted in a significant reduction in primary endpoint (P=0.005). At further sensitivity analyses, the exclusion of patients who did not receive an initial twice-daily dose regimen and the exclusion of patients enrolled after COVID-19 pandemic resulted in a significant reduction in MACE (P=0.01 and P=0.001, respectively), reflecting heterogeneity among studies. The present meta-analysis raises new questions over the indication, timing and dosing of colchicine in patients with recent MI.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0